Difference between revisions of "Afuresertib (GSK-2110183)"

Revision as of 16:12, 25 May 2015

Oral AKT1 inhibitor

Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. link to original article PubMed

Revision as of 03:33, 16 November 2014 (view source) Jwarner (talk \| contribs) m ← Older edit	Revision as of 16:12, 25 May 2015 (view source) Jwarner (talk \| contribs) m (Jwarner moved page Afuresertib to Afuresertib (GSK2110183)) Newer edit →
(No difference)